TRIFLUOX-DP: Safety of Trifluridine/Tipiracil as Replacement of Fluoropyrimidines (5-fluorouracil and Capecitabine) Based Chemotherapy as First Line Metastatic Colorectal or Gastroesophageal Cancer Regimens in Patients With Dihydropyrimidine Dehydrogenase Deficiency: a Phase II Trial

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 28 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Nivolumab (Primary) ; Oxaliplatin (Primary) ; Panitumumab (Primary) ; Tipiracil/trifluridine (Primary) ; Trastuzumab (Primary)
Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Gastric cancer; Oesophageal cancer; Rectal cancer
Focus Adverse reactions
Acronyms TRIFLUOX-DP

Most Recent Events

25 Mar 2025 Planned initiation date changed from 31 Jan 2025 to 1 Apr 2025.
13 Dec 2024 Planned initiation date changed from 20 Oct 2024 to 31 Jan 2025.
19 Sep 2024 Planned End Date changed from 21 Jun 2028 to 21 Oct 2028.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight